Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) have been given a consensus rating of “Hold” by the seven brokerages that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $12.75.
A number of equities analysts have issued reports on MRNS shares. Truist Financial reiterated a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday. StockNews.com upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday.
Check Out Our Latest Stock Report on Marinus Pharmaceuticals
Hedge Funds Weigh In On Marinus Pharmaceuticals
Marinus Pharmaceuticals Stock Up 10.9 %
Marinus Pharmaceuticals stock opened at $1.22 on Friday. The firm has a market cap of $67.02 million, a price-to-earnings ratio of -0.46 and a beta of 1.13. The business’s 50-day moving average price is $1.33 and its 200 day moving average price is $4.40. The company has a quick ratio of 2.93, a current ratio of 3.07 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $11.26.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Further Reading
- Five stocks we like better than Marinus Pharmaceuticals
- Stock Analyst Ratings and Canadian Analyst Ratings
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Investing In Preferred Stock vs. Common Stock
- Jeff Brown’s Exegesis AI Stock Picks
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.